Fertilizers and Agricultural Chemicals

HUAPONT LIFE SCIENCES

HUAPONT LIFE SCIENCES released FY2026 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 2.819 B, actual EPS CNY 0.0785

HUAPONT LIFE SCIENCES released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 2.426 B, actual EPS CNY 0.0513

HUAPONT LIFE SCIENCES released FY2025 earnings on April 22 After-Market BJT, actual revenue CNY 11.51 B, actual EPS CNY 0.3615

HUAPONT LIFE SCIENCES FY2026 Q1 Earnings Release on April 25 After-Market BJT

HUAPONT LIFE SCIENCES to Release FY2025 Earnings on April 23 After-Market (BJT)

HUAPONT LIFE SCIENCES released FY2025 9 Months earnings on October 28 Pre-Market (BJT), actual revenue CNY 9.086 B, actual EPS CNY 0.3101

HUAPONT LIFE SCIENCES released FY2025 Q3 earnings on October 28 Pre-Market BJT, actual revenue CNY 3.141 B, actual EPS CNY 0.1131

HUAPONT LIFE SCIENCES to Release FY2025 Q3 Earnings on October 29, Pre-Market BJT

HUAPONT LIFE SCIENCES released FY2025 Q2 earnings on August 19 After-Market BJT, actual revenue CNY 3.124 B, actual EPS CNY 0.1035

HUAPONT LIFE SCIENCES released FY2025 Semi-Annual earnings on August 19 After-Market (BJT), actual revenue CNY 5.945 B, actual EPS CNY 0.1968

HUAPONT LIFE SCIENCES to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Huanbang Health Subsidiary Obtains Drug Registration Certificate

Huabang Health's Secretary Responds to Investor Questions

Huabang Health Explains Employee Size and Business Scope of Linzhi Baisheng Pharmaceutical

Huabang Health Announces Board Chair and CEO Changes

Huabang Health 2024 Earnings Loss Due to Goodwill Impairment

Huabang Pharmaceutical Obtains Drug Registration Certificate for Loxoprofen Sodium Oral Solution

Huabang Health Announces Q1 2025 Earnings

Huabang Health Inc. Reports Net Loss of 299 Million Yuan in 2024

HUAPONT LIFE SCIENCES released FY2024 earnings on April 22 After-Market (BJT), actual revenue CNY 11.66 B, actual EPS CNY -0.1514

002004

On October 30th, HUAPONT LIFE SCIENCES stated on the interactive platform that the company has not yet engaged in brain-computer interface business

Zhitong

HUAPONT LIFE SCIENCES: The company has not yet engaged in the brain-computer interface business

300683

688098

300204

603367

300878

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit

HITECK

Shen Lian Biomedical

Staidson BioPharm

CISEN

WECOME

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

According to the Zhitong Finance APP, HUAPONT LIFE SCIENCES announced that its wholly-owned subsidiary Chongqing Huabong Pharmaceutical Co., Ltd. (referred to as "Huabong Pharmaceutical") recently received two specifications of the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Mometasone Furoate Cream. Mometasone Furoate Cream is mainly used for eczema, neurodermatitis, atopic dermatitis, and pruritus

HUAPONT LIFE SCIENCES' subsidiary has obtained the drug registration certificate for Mometasone Furoate Cream

HUAPONT LIFE SCIENCES announced that in the first half of 2025, operating revenue was 5.945 billion yuan, a year-on-year increase of 0.39%. Net profit was 388 million yuan, a year-on-year increase of 23.90%. The company plans to distribute a cash dividend of 2 yuan for every 10 shares based on a total of 1.973 billion shares

HUAPONT LIFE SCIENCES: Net profit of 388 million yuan in the first half of 2025, a year-on-year increase of 23.90%

301069

According to the Zhitong Finance APP, KS New Materials has disclosed a shareholder inquiry transfer plan. The shareholder participating in the inquiry transfer is HUAPONT LIFE SCIENCES, and the total number of shares to be transferred is 20 million, accounting for 4.75% of the company's total share capital

KS New Materials

Shareholder of KS New Materials, HUAPONT LIFE SCIENCES, plans to inquire about the transfer of 4.75% of the company's shares

HUAPONT LIFE SCIENCES announced that its wholly-owned subsidiary Chongqing Huabong Pharmaceutical has obtained the drug registration certificates for Fusidic Acid Cream and Fluticasone Propionate Cream issued by the National Medical Products Administration. This marks the official approval for the market launch of these two products, further enriching the company's product line in the dermatology field and enhancing its product matrix for the treatment of inflammatory skin diseases and other skin conditions

HUAPONT LIFE SCIENCES: Fusidic Acid Cream and Fluticasone Propionate Cream have obtained drug registration certificates

On May 14th, HUAPONT LIFE SCIENCES announced that the board of directors elected Zhang Songshan as the chairman of the ninth board of directors, elected Wang Rong as the vice chairman, and appointed Zhang Haian as the company's general manager

HUAPONT LIFE SCIENCES: Elected Zhang Songshan as Chairman

According to the Zhitong Finance APP, HUAPONT LIFE SCIENCES released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 2.821 billion yuan, a year-on-year decrease of 3.24%. The net profit attributable to shareholders of the listed company was 184 million yuan, a year-on-year increase of 18.50%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 170 million yuan, a year-on-year increase of 14.34%

HUAPONT LIFE SCIENCES released its first-quarter performance, with a net profit attributable to the parent company of 184 million yuan, a year-on-year increase of 18.50%

According to the Zhitong Finance APP, HUAPONT LIFE SCIENCES released its 2024 annual report. During the reporting period, the company achieved operating revenue of 11.665 billion yuan, a year-on-year increase of 0.60%. The net loss attributable to shareholders of the listed company was 299 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 338 million yuan. The basic loss per share was 0.1514 yuan

HUAPONT LIFE SCIENCES released its 2024 annual performance, turning from profit to a loss of 299 million yuan

According to the Zhitong Finance APP, HUAPONT LIFE SCIENCES announced that its wholly-owned subsidiary Chongqing Huabong Pharmaceutical Co., Ltd. (hereinafter referred to as "Huabong Pharmaceutical") recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Calcipotriol Betamethasone Ointment. Calcipotriol Betamethasone Ointment is an important compound preparation in the field of psoriasis treatment, mainly suitable for the local treatment of stable plaque psoriasis in adults

HUAPONT LIFE SCIENCES subsidiary obtains drug registration certificate for Calcipotriol and Betamethasone Ointment

HUAPONT LIFE SCIENCES(002004.SZ)